Redefining response in wet AMD to anti VEGF therapy based on non-OCTA versus OCTA evaluation
PURPOSE: Anti vascular endothelial growth factor (anti VEGF) has been the mainstay of treatment in wet age-related macular degeneration (AMD). Subsequent decision to continue anti VEGF therapy depends on the treatment response quantified by functional (visual acuity) and morphological (optical coherence tomography) parameters then categorized from good to poor.
METHODS: This study evaluates the agreement between OCT angiography (OCTA) and non-OCTA (logMAR VA plus OCT) to decide anti-VEGF treatment's continuity. After an anti VEGF treatment, on a follow up visit, a patient underwent non-OCTA evaluation (decision A) then OCTA evaluation (decision B) to judge the necessity of future anti VEGF application.
RESULTS: Out of 129 eyes, on 72 eyes (49%), there were agreements on both decision arms, but on 55 eyes (42%) there was disagreement. Particularly, disagreement on 47/55 eyes was important, where OCTA advised "continue anti VEGF" and non-OCTA advised "Stop anti VEGF" therapy. Cohen's Kappa for probability of agreement to continue anti VEGF was fair (0.33) and to stop anti VEGF therapy was none (0.1).
CONCLUSIONS: Based on resulting disagreements between the two modalities on deciding the continuity of anti VEGF, we conclude that OCTA must be considered in the conventional decision making algorithm in patients with wet AMD under anti VEGF therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
European journal of ophthalmology - 32(2022), 5 vom: 19. Sept., Seite 2719-2725 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khatri, Anadi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age related macular degeneration |
|---|
| Anmerkungen: |
Date Completed 12.08.2022 Date Revised 12.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/11206721211059349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333341244 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333341244 | ||
| 003 | DE-627 | ||
| 005 | 20231225221452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/11206721211059349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333341244 | ||
| 035 | |a (NLM)34796729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khatri, Anadi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Redefining response in wet AMD to anti VEGF therapy based on non-OCTA versus OCTA evaluation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2022 | ||
| 500 | |a Date Revised 12.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Anti vascular endothelial growth factor (anti VEGF) has been the mainstay of treatment in wet age-related macular degeneration (AMD). Subsequent decision to continue anti VEGF therapy depends on the treatment response quantified by functional (visual acuity) and morphological (optical coherence tomography) parameters then categorized from good to poor | ||
| 520 | |a METHODS: This study evaluates the agreement between OCT angiography (OCTA) and non-OCTA (logMAR VA plus OCT) to decide anti-VEGF treatment's continuity. After an anti VEGF treatment, on a follow up visit, a patient underwent non-OCTA evaluation (decision A) then OCTA evaluation (decision B) to judge the necessity of future anti VEGF application | ||
| 520 | |a RESULTS: Out of 129 eyes, on 72 eyes (49%), there were agreements on both decision arms, but on 55 eyes (42%) there was disagreement. Particularly, disagreement on 47/55 eyes was important, where OCTA advised "continue anti VEGF" and non-OCTA advised "Stop anti VEGF" therapy. Cohen's Kappa for probability of agreement to continue anti VEGF was fair (0.33) and to stop anti VEGF therapy was none (0.1) | ||
| 520 | |a CONCLUSIONS: Based on resulting disagreements between the two modalities on deciding the continuity of anti VEGF, we conclude that OCTA must be considered in the conventional decision making algorithm in patients with wet AMD under anti VEGF therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Age related macular degeneration | |
| 650 | 4 | |a OCT angiography | |
| 650 | 4 | |a optical coherence tomography | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Pandey, Araniko |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Kriti |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Kinsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Prasai, Gunjan |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Eli |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of ophthalmology |d 1996 |g 32(2022), 5 vom: 19. Sept., Seite 2719-2725 |w (DE-627)NLM012606944 |x 1724-6016 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2022 |g number:5 |g day:19 |g month:09 |g pages:2719-2725 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/11206721211059349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2022 |e 5 |b 19 |c 09 |h 2719-2725 | ||